Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|FT538||FT-538|FT 538||FT538 consists of a preparation of natural killer cells derived from induced pluripotent stem cells engineered to lack CD38 and to express an IL-15 receptor alpha fusion protein and a non-cleavable form of CD16, which potentially induces enhanced antibody-dependent cellular cytotoxicity against tumor cells (Blood (2019) 134 (Supplement_1): 133).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04614636||Phase I||Cyclophosphamide + Fludarabine Daratumumab + FT538 Elotuzumab + FT538 FT538||FT538 in Subjects With Advanced Hematologic Malignancies||Recruiting||USA||0|